Αποτελέσματα Αναζήτησης
17 Οκτ 2018 · In our thorough review of recent studies describing total and OOP costs along the cancer care continuum, we observed that, depending on age and disease stage, the net cost to all payers of common cancers can be expected to be between $20,000 and $100,000 in the initial year after diagnosis and ≥$60,000 at the end of life.
11 Μαρ 2021 · The optimal approach to cancer research impact evaluation is not clear. The aim of this study was to undertake a systematic review of review articles that describe approaches to impact assessment, and to identify examples of cancer research impact evaluation within these reviews.
27 Ιαν 2017 · Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding - PMC. Journal List. BMJ Open. v.7 (1); 2017. PMC5278265. As a library, NLM provides access to scientific literature.
5 Δεκ 2019 · To achieve success in improving the value of US cancer care, we must characterize the key cost drivers, identify how these cost drivers vary by cancer subtype, and ultimately determine how best to systematically improve underuse of high-value services and minimize the use of low-value services.
5 Δεκ 2019 · This systematic review highlights findings from modern analyses of the cost effectiveness of breast cancer care. We found that targeting general populations for cancer control interventions has reasonable costs per QALY saved compared with doing nothing but that risk-targeted approaches lowered costs without major trade-offs in lives saved.
Abstract. Background. Optimal cancer care entails the coordination among multiple providers, continued follow-up and surveillance over time. The patient-centered care brings opportunities to improve the delivery of cancer care.
16 Σεπ 2021 · Recognition of cancer-related financial burden has led to initiatives towards improving price transparency and value-based care in the clinical setting. In recent years, medical organisations from many countries, have recommended greater transparency about the costs of treatment.
